A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback